Related Experiment Video
Updated: Apr 14, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Targeting the hyaluronic acid-CD44 axis in hepatocellular carcinoma
Georgia Zancotti1, Gisela Weiz2, Cyrollah Disoma1
1Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park, Basovizza, Trieste 34049, Italy; Doctoral School of Molecular Biomedicine, Department of Life Sciences, University of Trieste, Trieste 34149, Italy.
Abstract:
Hepatocellular carcinoma (HCC) remains a major global health challenge, with rising incidence, frequent development of drug resistance, and limited long-term survival despite advances in systemic therapies. Within the tumor microenvironment, the interaction between hyaluronic acid (HA) and cluster of differentiation 44 (CD44) is linked to tumor progression and therapeutic failure. Accordingly, targeting the HA-CD44 signaling axis represents a promising strategy to overcome resistance. This review highlights potential approaches, including inhibition of HA synthesis, enzymatic HA degradation, CD44 blockade, and HA-based nanocarriers for selective drug delivery, alone or combined with existing therapies. Leveraging HA-CD44 biology may help refine profiling and support the development of more personalized treatments, ultimately enhancing outcomes for HCC patients.
